Saturday, August 29, 2026

Dirty Fetish Reveal: Lee Admits He’s Dying To Say SORRY To Kim Jong Un, But Fears Media

President Lee Jae Myung reflects on anti-North Korean leaflets, suggesting a national apology to ease tensions amidst concerns of war.

Is North Korea’s Claim of South Korean Drone Intrusion True? Explore the Joint Investigation

A joint military-police investigation is underway in South Korea regarding alleged drone incursions into North Korean airspace.

NAVER to Invest Heavily in Creator Ecosystem as AI Search Competition Shifts to Data Quality

Naver will support creators of AI search content with 20 billion won annually to enhance AI search service competitiveness.

Tag: drug development

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

SK Biopharm CEO Lee Dong-hoon: “AI and open innovation are key to drug development” [BIO USA]

SK Biopharmaceuticals focuses on open innovation and AI for drug development, aiming to enhance CNS therapies and expand into new modalities.

U.S. FDA to Streamline IND Process: What It Means for Asian Biotech Competitiveness in 2027

The U.S. aims to streamline drug approval processes to compete with China and Australia in attracting clinical trials, enhancing biotech growth.

National New Drug Development Project Group Holds 2026 Workshop on Investment Review Strategy

The National New Drug Development Project Group held a workshop to discuss drug development trends and investment strategies for future projects.

HLB BioStep Signs Strategic MOU with CLIPS BnC… Toward Integrated Preclinical and Clinical Development

HLB BioStep and CLIPS BnC sign MOU to enhance collaboration between preclinical and clinical stages of drug development.

How JNPMEDI Plans to Achieve 250% Revenue Growth in 2026: A Guide for Pharma Innovators

JNPMEDI aims to enhance its global role in drug and medical device development, achieving significant growth and expanding partnerships.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.